Meeting
2014 Genitourinary Cancers Symposium
A predicitve algorithm for response to abiraterone in metastatic castration relapsed prostate cancer (CRPC).
Authors
Mehran Afshar
Queen Elizabeth Hospital, Birmingham, United Kingdom
Mehran Afshar , Fawaz Al-Alloosh , Nicholas David James , Helen Clarke , Sarah Pirrie , Emilio Porfiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 238)
DOI
10.1200/jco.2014.32.4_suppl.238
Abstract #
238
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Primary resistance in docetaxel and androgen deprivation therapy in metastatic castrate sensitive prostate cancer patients.
First Author: Athanasios Pouptsis
Poster
2018 Genitourinary Cancers Symposium
Abiraterone or docetaxel in men with metastatic castration-sensitive prostate cancer: A pooled analysis of castration resistance-free survival and toxicity.
First Author: Joelle Helou
Poster
2015 Genitourinary Cancers Symposium
Correlation between time to prostate cancer metastasis and overall survival after androgen deprivation therapy initiation.
First Author: Lillian Werner
Poster
2013 ASCO Quality Care Symposium
Application of a novel method weighing drug costs against survival in castrate-resistant prostate cancer cancer.
First Author: Helmy M. Guirgis